Presentation is loading. Please wait.

Presentation is loading. Please wait.

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

Published byBrittany Matthews Modified over 5 years ago

Similar presentations

Presentation on theme: "The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;"— Presentation transcript:

1 The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab; Chemo-P, platinum-based chemotherapy; IO, immunotherapy; D+R, docetaxel plus ramucirumab; D, docetaxel; Nivo, nivolumab; Atezo, atezolizumab; 1st, first; 2nd, second; 3rd, third; PD-L1, programmed cell death-1 ligand. The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab; Chemo-P, platinum-based chemotherapy; IO, immunotherapy; D+R, docetaxel plus ramucirumab; D, docetaxel; Nivo, nivolumab; Atezo, atezolizumab; 1st, first; 2nd, second; 3rd, third; PD-L1, programmed cell death-1 ligand. Yi-Chen Zhang et al. ESMO Open 2017;2:e000129 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;"

Similar presentations

N Engl J Med; Volume 373(17): ; October 22, 2015

N Engl J Med; Volume 373(17): ; October 22, 2015
advanced lung adenocarcinoma subtype

advanced lung adenocarcinoma subtype
Volume 64, Pages e1-e3 (January 2017)

Volume 64, Pages e1-e3 (January 2017)
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.

Mean density of CD8+ and Foxp3+ lymphocytes in tumour infiltrate before (pre-TPF) and after (post-TPF) induction chemotherapy, (A) Patients’ tumours with.
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Similar presentations

Ads by Google